{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:54:30Z","timestamp":1789574070811,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,24]],"date-time":"2011-03-24T00:00:00Z","timestamp":1300924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00198-011-1608-z","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T18:03:14Z","timestamp":1300903394000},"page":"247-254","source":"Crossref","is-referenced-by-count":33,"title":["Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis"],"prefix":"10.1007","volume":"23","author":[{"given":"C. W.","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,24]]},"reference":[{"key":"1608_CR1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1608_CR2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) study group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1608_CR3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1608_CR4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crin\u00f2 L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Th\u00fcrlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420\u2013432","journal-title":"Ann Oncol"},{"key":"1608_CR5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1608_CR6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","volume":"356","author":"S Cummings","year":"2007","unstructured":"Cummings S, Schwartz A, Black D (2007) Alendronate and atrial fibrillation [Letter]. N Engl J Med 356:1895\u20131896","journal-title":"N Engl J Med"},{"key":"1608_CR7","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ (2004) Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation 110:1042\u20131046","journal-title":"Circulation"},{"key":"1608_CR8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/archinte.159.10.1118","volume":"159","author":"SL Kopecky","year":"1999","unstructured":"Kopecky SL, Gersh BJ, McGoon MD, Chu CP, Ilstrup DM, Chesebro JH, Whisnant JP (1999) Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 159:1118\u20131122","journal-title":"Arch Intern Med"},{"key":"1608_CR9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","volume":"336","author":"HT S\u00f8rensen","year":"2008","unstructured":"S\u00f8rensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813\u2013816","journal-title":"BMJ"},{"key":"1608_CR10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","volume":"103","author":"TJ Bunch","year":"2009","unstructured":"Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lapp\u00e9 DL, Osborn JS, Day JD (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824\u2013828","journal-title":"Am J Cardiol"},{"key":"1608_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/gme.0b013e3181b34749","volume":"17","author":"WF Huang","year":"2010","unstructured":"Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR (2010) Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 17:57\u201363","journal-title":"Menopause"},{"key":"1608_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","volume":"265","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581\u2013592","journal-title":"J Intern Med"},{"key":"1608_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","volume":"32","author":"Y Loke","year":"2009","unstructured":"Loke Y, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219\u2013228","journal-title":"Drug Saf"},{"key":"1608_CR14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2009.11.041","volume":"142","author":"R Bhuriya","year":"2010","unstructured":"Bhuriya R, Singh M, Molnar J, Arora R, Khosla S (2010) Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 142:213\u2013217","journal-title":"Int J Cardiol"},{"key":"1608_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.amjopharm.2009.12.004","volume":"7","author":"BJ Gates","year":"2009","unstructured":"Gates BJ, Sonnett TE, DuVall CA, Dobbins EK (2009) Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 7:293\u2013323","journal-title":"Am J Geriatr Pharmacother"},{"key":"1608_CR16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0002-9343(99)00028-5","volume":"106","author":"P Recke von der","year":"1999","unstructured":"von der Recke P, Hansen M, Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106:273\u2013278","journal-title":"Am J Med"},{"key":"1608_CR17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","volume":"48","author":"V Fuster","year":"2006","unstructured":"Fuster V, Ryd\u00e9n LE, Cannom DS et al (2006) ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48:854\u2013906","journal-title":"J Am Coll Cardiol"},{"key":"1608_CR18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","volume":"168","author":"SR Heckbert","year":"2008","unstructured":"Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826\u2013831","journal-title":"Arch Intern Med"},{"key":"1608_CR19","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1359\/JBMR.050711","volume":"20","author":"LB Tank\u00f3","year":"2005","unstructured":"Tank\u00f3 LB, Christiansen C, Cox DA, Geiger MJ, Mcnabb MA, Cummings SR (2005) Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912\u20131920","journal-title":"J Bone Miner Res"},{"key":"1608_CR20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/0004563011901037","volume":"38","author":"SD Vasikaran","year":"2001","unstructured":"Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38:608\u2013623","journal-title":"Ann Clin Biochem"},{"key":"1608_CR21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101\u2013111","journal-title":"Clin Exp Immunol"},{"key":"1608_CR22","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"A Roelofs","year":"2006","unstructured":"Roelofs A, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s\u20136230s","journal-title":"Clin Cancer Res"},{"key":"1608_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","volume":"18","author":"A Sauty","year":"1996","unstructured":"Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133\u2013139","journal-title":"Bone"},{"key":"1608_CR24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"D Schweitzer","year":"1995","unstructured":"Schweitzer D, Oostendorp-Van De Ruit M, Van der Pluijm G, L\u00f6wik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylamino hydroxypropylidene bisphosphonate. J Bone Miner Res 10:956\u2013962","journal-title":"J Bone Miner Res"},{"key":"1608_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/gme.0b013e318194cafd","volume":"16","author":"M Celiloglu","year":"2009","unstructured":"Celiloglu M, Aydin Y, Balci P, Kolamaz T (2009) The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689\u2013693","journal-title":"Menopause"},{"key":"1608_CR26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/CIRCULATIONAHA.105.593418","volume":"114","author":"I Kronzon","year":"2006","unstructured":"Kronzon I, Tunick PA (2006) Aortic atherosclerotic disease and stroke. Circulation 114:63\u201375","journal-title":"Circulation"},{"key":"1608_CR27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0022-2143(96)90079-7","volume":"127","author":"R Ylitalo","year":"1996","unstructured":"Ylitalo R, M\u00f6nkk\u00f6nen J, Urtti A, Ylitalo P (1996) Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 127:200\u2013206","journal-title":"J Lab Clin Med"},{"key":"1608_CR28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0773.1998.tb01455.x","volume":"83","author":"R Ylitalo","year":"1998","unstructured":"Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, L\u00e4hteenm\u00e4ki T, Ylitalo P, P\u00f6rsti I (1998) Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83:125\u2013131","journal-title":"Pharmacol Toxicol"},{"key":"1608_CR29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bone.2008.03.030","volume":"43","author":"A Luckish","year":"2008","unstructured":"Luckish A, Cernes R, Boaz M, Gavish D, Matas Z, Fux A, Shargorodsky M (2008) Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors. Bone 43:279\u2013283","journal-title":"Bone"},{"key":"1608_CR30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S8756-3282(02)00924-9","volume":"32","author":"A Montagnani","year":"2003","unstructured":"Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32:15\u201319","journal-title":"Bone"},{"key":"1608_CR31","first-page":"252","volume":"29","author":"E Guney","year":"2008","unstructured":"Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252\u2013255","journal-title":"Neuro Endocrinol Lett"},{"key":"1608_CR32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2000.15.3.599","volume":"15","author":"S Adami","year":"2000","unstructured":"Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599\u2013604","journal-title":"J Bone Miner Res"},{"key":"1608_CR33","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555\u20131565","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl .2","key":"1608_CR34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1542\/peds.2006-2023H","volume":"119","author":"RG Russell","year":"2007","unstructured":"Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(suppl .2):150\u2013162","journal-title":"Pediatrics"},{"key":"1608_CR35","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","volume":"20","author":"G Rodan","year":"2004","unstructured":"Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291\u20131300","journal-title":"Curr Med Res Opin"},{"key":"1608_CR36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-009-0003-6","volume":"7","author":"P Geusens","year":"2009","unstructured":"Geusens P (2009) Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7:12\u201317","journal-title":"Curr Osteoporos Rep"},{"key":"1608_CR37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3346\/jkms.2005.20.1.26","volume":"20","author":"JH Jeong","year":"2005","unstructured":"Jeong JH (2005) Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40\u00a0years. J Korean Med Sci 20:26\u201330","journal-title":"J Korean Med Sci"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1608-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1608-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:08:38Z","timestamp":1558624118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1608-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,24]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1608"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1608-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,24]]}}}